Compare Incyte Corporation (INCY) vs Invesco S&P 500 High Div Low Volatility ETF (SPHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Invesco S&P 500 High Div Low Volatility ETF — how do they compare? Incyte Corporation trades at $121.35 (market cap $24.54B), while Invesco S&P 500 High Div Low Volatility ETF trades at $52.42. Which is the better fit depends on your goals.
| INCY | SPHD | |
|---|---|---|
Market Cap | $24.54B | — |
Sector | Health | — |
52-Week High | $129.93 | $53.55 |
52-Week Low | $81.61 | $46.96 |
Enterprise Value | $20.04B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $121.55, near its consensus price target of $122.82, with a bullish technical signal and strong recent earnings beats. Revenue grew to $5.14B in 2025, with net income surging to $1.29B, reflecting robust profitability. The company raised its 2026 revenue outlook following strong Q2 results and positive developments like EU approval for Opzelura.
Outlook is positive with solid fundamentals and analyst support, though risks include competitive pressures and reliance on key products. The stock offers growth potential but requires monitoring of execution and market conditions.
SPHD trades at $52.26, down 0.29% today, with a bullish technical signal supported by moving averages. The ETF focuses on high-dividend, low-volatility S&P 500 stocks, offering monthly income. Recent news highlights investor interest in dividend and value strategies amid market volatility, with articles from Zacks and 24/7 Wall Street in August 2026 emphasizing its role in retirement portfolios.
The outlook for SPHD is stable, appealing for income-focused investors seeking lower volatility. Key opportunities include consistent dividends and defensive positioning, while risks involve interest rate sensitivity and potential underperformance in strong bull markets. Analyst sentiment is generally positive for its strategy in current conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Invesco S&P 500 High Div Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the “index Provider”) compiles, maintains and calculates the underlying index, which is designed to measure the performance of 50 least volatile high yielding constituents of the S&P 500 ® Index in the past year.
Read more on SPHD →
